CD274 and non-small cell lung carcinoma: Several of these options, such as the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and several programmed cell death-1 receptor/programmed cell death-ligand 1 inhibitors (PD-1/PD-L1), are already well-established in the management of advanced NSCLC [8].